Aclaris Therapeutics, Inc. ACRS
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.40M | 8.22M | 8.37M | 7.83M | 15.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.40M | 8.22M | 8.37M | 7.83M | 15.74M |
| Cost of Revenue | 72.40M | 70.49M | 64.27M | 59.93M | 60.20M |
| Gross Profit | -66.00M | -62.28M | -55.91M | -52.10M | -44.46M |
| SG&A Expenses | 24.41M | 23.24M | 22.58M | 21.97M | 21.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.81M | 93.73M | 86.85M | 81.90M | 81.55M |
| Operating Income | -90.41M | -85.51M | -78.48M | -74.08M | -65.81M |
| Income Before Tax | -79.63M | -75.74M | -69.66M | -64.92M | -141.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.63 | -75.74 | -69.66 | -64.92 | -141.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.63M | -75.74M | -69.66M | -64.92M | -141.68M |
| EBIT | -90.41M | -85.51M | -78.48M | -74.08M | -65.81M |
| EBITDA | -68.45M | -85.49M | -78.43M | -74.00M | -65.70M |
| EPS Basic | -0.59 | -0.59 | -0.56 | -0.53 | -1.38 |
| Normalized Basic EPS | -0.37 | -0.36 | -0.34 | -0.32 | -0.29 |
| EPS Diluted | -0.59 | -0.59 | -0.56 | -0.53 | -1.38 |
| Normalized Diluted EPS | -0.37 | -0.36 | -0.34 | -0.32 | -0.29 |
| Average Basic Shares Outstanding | 543.66M | 516.83M | 496.68M | 490.26M | 462.90M |
| Average Diluted Shares Outstanding | 543.66M | 516.83M | 496.68M | 490.26M | 462.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |